Search Videos and More
News
Building a System of Focused Care for Lobular Breast Cancer
How Dana-Farber investigators are pioneering new approaches to help understand, diagnose, and treat this distinct form of breast cancer
News
Dana-Farber Science Backs Development of Targeted Therapy for Rare GIST Cancer
Some things are best kept under lock and key, like oncogenes, which are genes that are associated with cancer growth because they signal cells to grow rapidly.
News
Targeting CDK2 Could Boost Immunotherapy Response in Patients With a Wide Range of Cancers, According to Dana-Farber Science
New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow range of cancers, could potentially be more broadly applicable to a wide range of cancers when combined with immunotherapy.
News
FDA Approves First CELMoD Agent, with Dana-Farber Helping Advance its Development
The U.S. Food and Drug Administration has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma, making it the first approved cereblon E3 ligase modulator (CELMoD) for this disease.
News
Dana-Farber Investigators Develop Protein Degrader Discovery Platform and Find First-in-Kind Metabolically Activated Molecular Glue Degrader
Investigators at Dana-Farber Cancer Institute have developed a platform for systematically discovering molecular glues that could become protein degradation drug candidates. The platform could help drug developers dramatically expand the range of disease-related proteins that can be therapeutically targeted for elimination via protein degradation.
News
Collaborative Team Doubles Number of In Vitro Patient-Derived Cancer Models Available for Research
A collaborative team led by investigators from Dana-Farber Cancer Institute and elsewhere developed 665 next-generation patient-derived cancer models across 27 common and rare forms of cancer and made the models plus relevant clinical and molecular data available as a resource to researchers around the globe to accelerate cancer advances.
News
FDA Approves Personalized Blood-Test Guided Immunotherapy for Bladder Cancer, Backed by Dana-Farber Science
When patients with bladder cancer complete treatment that is intended to cure the cancer, they may be left wondering if there is anything else they should do to keep the cancer from coming back.
News
Dana-Farber Researchers Identify CDK8 as a Potential Therapeutic Target for Alveolar Rhabdomyosarcoma
Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma (aRMS), an aggressive childhood cancer with poor survival and few targeted treatment options, to identify new treatment vulnerabilities. Using a network-based analysis of large functional genomic datasets, they found that aRMS cells depend on CDK8, a protein involved in controlling gene activity.
News
Three-Drug Treatment Shows Promise for Patients with Rare Blood Cancer BPDCN
A three-drug treatment combination led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer, in a phase 2 clinical trial led by researchers at Dana-Farber Cancer Institute.
News
Dana-Farber Research Supports FDA Approval of New Therapy for “Double-Positive” Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with “double-positive” metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute.
News
The RAS Moment for Pancreatic Cancer Research
Dana-Farber investigators are at the forefront of a new era in RAS therapeutics for pancreatic cancer research
News
Rapid Epigenetic Test Could Speed Diagnostics for Acute Leukemias
Acute leukemias are life-threatening blood conditions that need urgent treatment. Approved targeted therapies such as BCL2, IDH, and menin inhibitors have expanded treatment options for certain patients, but determining if a given patient might benefit from one of these treatments can take time. Doctors need to order multiple complex diagnostic workups that can take days or even weeks to complete.